About Susan Thompson

In addition to being an author and speaker, Susan Thompson serves as the Technical Director of Indianapolis based VxP Pharma.

The Vero Vaccine Production Pipeline

The Vero platform’s upstream and downstream processing stages are designed for maximum efficiency and safety, as well as purity of the final product. Despite many recent advances in vaccine development technology, the actual process of bringing new vaccines to the clinical trial stage often remains cumbersome and slow. Even the most elaborate recombinant technologies and vector systems may not integrate smoothly into an existing manufacturing pipeline, and inefficiencies and safety issues may emerge at any step of the process.

By |2018-02-07T09:34:00-05:00October 12th, 2017|Research & Development|0 Comments

Vero Cell Platform Technology

This cell development platform has proven effective in the creation of a number of viral vaccines. by Susan Thompson, Technical Director at VxP Biologics Recent years have witnessed a significant amount of innovation in technologies for the development of novel vaccines. These technologies include new vector systems for delivering attenuated vaccines, recombinant technologies for generating [...]

By |2018-02-07T09:33:45-05:00October 1st, 2017|Research & Development|0 Comments

Vector Development

The creation, production and storage of viral vectors all pose highly unusual challenges. by Susan Thompson, Technical Director at VxP Biologics Traditional viral vaccines use attenuated or inactivated forms of viruses to trigger and “train” the body’s immune responses. In recent years, however, pharmaceutical developers have also begun to use viruses as vectors to deliver [...]

By |2018-02-07T09:34:35-05:00September 19th, 2017|Manufacturing|0 Comments

Clinical Stage Products

Emerging technologies offer exciting opportunities for the development of novel therapies. by Susan Thompson, Technical Director at VxP Biologics Although commercial sales are certainly a desirable target for pharmaceutical development, they’re far from the only reason to invest in new products. In a number of fields, pharma developers are partnering with contract manufacturing organizations (CMOs) [...]

By |2018-02-07T09:33:40-05:00September 3rd, 2017|Research & Development|0 Comments

New Investments and Approvals Spur the Development of Biologics

Although still expensive to develop and produce, large molecules are rapidly taking over. by Susan Thompson, Technical Director at VxP Biologics For most of the previous century, much of pharmaceutical research focused on the development of small-molecule “blockbuster” drugs, which treated a wide variety of diseases for a great number of patients, and could thus [...]

By |2018-02-07T09:33:52-05:00June 18th, 2017|Manufacturing, Research & Development|0 Comments

Sterile Injectables for Clinical Trials

Growth continues, but logistical and regulatory hurdles limit worldwide supplies. by Susan Thompson, Technical Director at VxP Biologics The global market for sterile injectables continues to expand at an impressive rate. In 2015, this market was valued at $299.7 billion; and its compound annual growth rate (CAGR) is projected at 6.9 percent, at least through [...]

By |2018-02-07T09:33:35-05:00June 6th, 2017|Manufacturing, Research & Development|0 Comments
Go to Top